Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744876 | 0.92 | TDP1 (0.46) | TDP1ATMMAPTPKMCA12 | |
| SCHEMBL27708019 | 0.84 | GPR35 (0.50) | TDP1MAPTCA12CA1CA2 | |
| SCHEMBL518140 | 0.84 | GPR35 (0.50) | TDP1ATMMAPTCA12CA1 | |
| SCHEMBL29740055 | 0.82 | ATM (0.55) | TDP1ATMMAPTPKMMAPK1 | |
| SCHEMBL14691657 | 0.82 | CA12 (0.48) | TDP1MAPTCA12CA1CA2 | |
| SCHEMBL8579982 | 0.82 | CA12 (0.48) | TDP1MAPTCA12CA1CA2 | |
| SCHEMBL310906 | 0.82 | ATM (0.55) | TDP1ATMMAPTPKMMAPK1 | |
| SCHEMBL7335 | 0.78 | ATM (0.55) | TDP1ATMMAPTPKMMAPK1 | |
| SCHEMBL2326899 | 0.78 | TDP1 (0.50) | TDP1ATMMAPTCA12CA1 | |
| SCHEMBL29663529 | 0.78 | ATM (0.55) | TDP1ATMMAPTPKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117105916-B | Benzofuran compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117105916-A | Benzofuran compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-9624208-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624208-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624208-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150252034-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150252034-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150252034-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC | 2015-09-10 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-101200429-A | 2-nitro-4,5-dihalogenated phenol and 2-amino-4,5-dihalogenated phenol as well as its salt and method for synthesizing the same | SHANGHAI RUIZHI CHEMICAL STUDY (CN) | 2008-06-18 | — | — | CN | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252034-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN7A, CACNA1E, SCN1A | TDP1 1368/4885ATM 4072/4885MAPT 2940/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | TDP1 3338/4885ATM 315/4885MAPT 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.